Inhibikase Therapeutics Inc. (NASDAQ: IKT)
$1.51
-0.0300 ( -1.95% ) 7.4K
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
Market Data
Open
$1.51
Previous close
$1.54
Volume
7.4K
Market cap
$10.46M
Day range
$1.41 - $1.55
52 week range
$0.79 - $3.82
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
def | Proxies and info statements | 3 | Jun 20, 2024 |
8-k | 8K-related | 13 | Jun 10, 2024 |
pre | Proxies and info statements | 3 | Jun 10, 2024 |
8-k | 8K-related | 27 | May 20, 2024 |
10-q | Quarterly Reports | 62 | May 15, 2024 |
8-k | 8K-related | 39 | Apr 30, 2024 |
def | Proxies and info statements | 3 | Apr 26, 2024 |
ars | Annual reports | 1 | Apr 26, 2024 |
8-k | 8K-related | 15 | Apr 19, 2024 |
pre | Proxies and info statements | 3 | Apr 15, 2024 |